Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per share...
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations.
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
Stocks Settle Mostly Lower on Chip Stock Weakness
The S&P 500 Index ($SPX ) (SPY ) Friday closed down by -0.19%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.24%. Stocks...